COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Focosi, Daniele [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease - Lopategi, A. ELSEVIER, 2016, official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, Oxford |
|---|---|
| Übergeordnetes Werk: |
volume:60 ; year:2021 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.transci.2021.103071 |
|---|
| Katalog-ID: |
ELV054489881 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV054489881 | ||
| 003 | DE-627 | ||
| 005 | 20230626040316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2021.103071 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica |
| 035 | |a (DE-627)ELV054489881 | ||
| 035 | |a (ELSEVIER)S1473-0502(21)00021-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Focosi, Daniele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| 264 | 1 | |c 2021transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. | ||
| 520 | |a The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. | ||
| 650 | 7 | |a COVID-19 |2 Elsevier | |
| 650 | 7 | |a Immune deficiencies |2 Elsevier | |
| 650 | 7 | |a SARS-CoV-2 |2 Elsevier | |
| 650 | 7 | |a Congenital |2 Elsevier | |
| 650 | 7 | |a Neutralizing antibodies |2 Elsevier | |
| 650 | 7 | |a Agammaglobulinemia |2 Elsevier | |
| 650 | 7 | |a Transplantation |2 Elsevier | |
| 650 | 7 | |a Hypogammaglobulinemia |2 Elsevier | |
| 650 | 7 | |a Convalescent plasma |2 Elsevier | |
| 650 | 7 | |a Alymphocytosis |2 Elsevier | |
| 700 | 1 | |a Franchini, Massimo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier [u.a.] |a Lopategi, A. ELSEVIER |t Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |d 2016 |d official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |g Oxford |w (DE-627)ELV01380703X |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.transci.2021.103071 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_252 | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 3 |h 0 | ||
| author_variant |
d f df |
|---|---|
| matchkey_str |
focosidanielefranchinimassimo:2021----:oi1nurlznatbdbsdhrpeihmrlmueeii |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2021 |
| allfields |
10.1016/j.transci.2021.103071 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica (DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Focosi, Daniele verfasserin aut COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier Franchini, Massimo oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:60 year:2021 number:3 pages:0 https://doi.org/10.1016/j.transci.2021.103071 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 60 2021 3 0 |
| spelling |
10.1016/j.transci.2021.103071 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica (DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Focosi, Daniele verfasserin aut COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier Franchini, Massimo oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:60 year:2021 number:3 pages:0 https://doi.org/10.1016/j.transci.2021.103071 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 60 2021 3 0 |
| allfields_unstemmed |
10.1016/j.transci.2021.103071 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica (DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Focosi, Daniele verfasserin aut COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier Franchini, Massimo oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:60 year:2021 number:3 pages:0 https://doi.org/10.1016/j.transci.2021.103071 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 60 2021 3 0 |
| allfieldsGer |
10.1016/j.transci.2021.103071 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica (DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Focosi, Daniele verfasserin aut COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier Franchini, Massimo oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:60 year:2021 number:3 pages:0 https://doi.org/10.1016/j.transci.2021.103071 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 60 2021 3 0 |
| allfieldsSound |
10.1016/j.transci.2021.103071 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica (DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Focosi, Daniele verfasserin aut COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier Franchini, Massimo oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:60 year:2021 number:3 pages:0 https://doi.org/10.1016/j.transci.2021.103071 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 60 2021 3 0 |
| language |
English |
| source |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:60 year:2021 number:3 pages:0 |
| sourceStr |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:60 year:2021 number:3 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
COVID-19 Immune deficiencies SARS-CoV-2 Congenital Neutralizing antibodies Agammaglobulinemia Transplantation Hypogammaglobulinemia Convalescent plasma Alymphocytosis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| authorswithroles_txt_mv |
Focosi, Daniele @@aut@@ Franchini, Massimo @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01380703X |
| dewey-sort |
3610 |
| id |
ELV054489881 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054489881</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626040316.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2021.103071</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054489881</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(21)00021-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Focosi, Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune deficiencies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Congenital</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibodies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Agammaglobulinemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypogammaglobulinemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Convalescent plasma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alymphocytosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franchini, Massimo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:60</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2021.103071</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">60</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Focosi, Daniele |
| spellingShingle |
Focosi, Daniele ddc 610 bkl 44.44 Elsevier COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| authorStr |
Focosi, Daniele |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01380703X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis |
| topic_browse |
ddc 610 bkl 44.44 Elsevier COVID-19 Elsevier Immune deficiencies Elsevier SARS-CoV-2 Elsevier Congenital Elsevier Neutralizing antibodies Elsevier Agammaglobulinemia Elsevier Transplantation Elsevier Hypogammaglobulinemia Elsevier Convalescent plasma Elsevier Alymphocytosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m f mf |
| hierarchy_parent_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| hierarchy_parent_id |
ELV01380703X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01380703X |
| title |
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| ctrlnum |
(DE-627)ELV054489881 (ELSEVIER)S1473-0502(21)00021-5 |
| title_full |
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| author_sort |
Focosi, Daniele |
| journal |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| journalStr |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Focosi, Daniele |
| container_volume |
60 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Focosi, Daniele |
| doi_str_mv |
10.1016/j.transci.2021.103071 |
| dewey-full |
610 |
| title_sort |
covid-19 neutralizing antibody-based therapies in humoral immune deficiencies: a narrative review |
| title_auth |
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| abstract |
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. |
| abstractGer |
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. |
| abstract_unstemmed |
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 |
| container_issue |
3 |
| title_short |
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review |
| url |
https://doi.org/10.1016/j.transci.2021.103071 |
| remote_bool |
true |
| author2 |
Franchini, Massimo |
| author2Str |
Franchini, Massimo |
| ppnlink |
ELV01380703X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.transci.2021.103071 |
| up_date |
2024-07-06T21:51:52.954Z |
| _version_ |
1803868137540550656 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054489881</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626040316.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2021.103071</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001440.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054489881</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(21)00021-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Focosi, Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS−COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti−COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative review will be to critically discuss the literature evidence on CP use in these categories of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune deficiencies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Congenital</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibodies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Agammaglobulinemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transplantation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypogammaglobulinemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Convalescent plasma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alymphocytosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franchini, Massimo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:60</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2021.103071</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">60</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4007616 |